IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML)
Status:
Terminated
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
In this phase I extension study, the investigators seek to test the safety of both higher
doses of plerixafor as well as intravenous dosing to maximize inhibition of the target,
CXCR4.
Phase:
Phase 1
Details
Lead Sponsor:
Washington University School of Medicine
Treatments:
Cytarabine Etoposide Etoposide phosphate JM 3100 Mitoxantrone Plerixafor